Interprofessional Perspectives on the Evolving Heart Failure Treatment Paradigm: Harnessing Novel Therapeutics to Optimize Outcomes & Overcome Disparities in Care
This educational activity is targeted to cardiologists, primary care physicians, nurse practitioners, nurses, physician assistants, pharmacists, and other members of the interprofessional, multidisciplinary heart failure (HF) care team.
- Review the robust clinical gravity of heart failure (HF), at both the individual and population levels, and identify the pathophysiologic distinctions between HFrEF and HFpEF.
- Appraise the impact of social determinants of health (SDOH) on HF outcomes and evaluate interprofessional approaches for mitigating and overcoming health inequities and disparities in HF care.
- Summarize recent updates to expert consensus treatment guidelines and guideline-directed medical therapy (GDMT) in HF, with a focus on completed and ongoing clinical trials and evidence-based therapeutic options in HFrEF.
- Interpolate novel agents into established HFrEF GDMT regimens and examine how innovative treatment targets and pharmacologic mechanisms are augmenting and optimizing traditional approaches.
- Using a real world, case-based format, design evidence-supported treatment plans for HFrEF that incorporate GDMT, novel therapies, and adaptive strategies for promoting equitable outcomes for all patients.
Supported through an independent educational grant from Merck.
Presented by Creative Educational Concepts, LLC.
Muthiah Vaduganathan, MD, MPH
Harvard Medical School
Brigham and Women’s Hospital
Dr. Vaduganathan is a cardiologist at Brigham and Women’s Hospital and Harvard Medical School (Boston, MA) He is interested in drug development and clinical trials of cardiometabolic therapies. He has authored or co-authored more than 275 peer-reviewed publications.
Dr. Vaduganathan serves on the editorial board of the European Journal of Heart Failure and JACC Heart Failure (Social Media / CME Editor). He serves on the ACCF/AHA Task Force on Performance Measures and is a co-chair on an FDA Think Tank on improving future clinical trials in HF. He participates as a Clinical Endpoints Committee member for ongoing advanced-phase trials in HF / post-MI LV dysfunction.
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Bryan Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Debra Moser, PhD, RN, FAAN–has no relevant financial relationships to disclose in relation to the content of this activity.
Muthiah Vaduganathan, MD, MPH–has disclosed that he is a consultant for American Regent, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, and Sanofi; Amgen, Bayer AG, Boehringer Ingelheim, AstraZeneca, Roche Diagnostics, Occlutech, Impulse Dynamics, Novartis, Bayer AG, Galmed. He is also a member of the speakers’ bureau for Novartis and Roche Diagnostics.
Kim K. Birtcher, M.S, PharmD, AACC, FNLA, BCPS-AQ Cardiology, CDCES–has no relevant financial relationships to disclose in relation to the content of this activity.
Tina L. Trieu, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1 hour of Interprofessional Continuing Education (IPCE) credit for learning and change.
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-21-015-L01-P)
This activity is designated for 1.0 contact hour.
Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 IPCE
- 1.00 Participation